TX45 produced acute, directionally favorable hemodynamic and echocardiographic changes in PH-HFrEF after a single intravenous dose: pulmonary capillary wedge pressure fell 29.2% (95% CI, -36.0% to -22.4%), total pulmonary resistance fell 29.2% (-37.1% to -21.3%), mean pulmonary artery pressure fell 19.3% (-24.8% to -13.8%), and cardiac output rose 17.3% (+5.2% to +29.3%) across 14 patients over the first 8 hours post-dose. Pulmonary vascular resistance declined 19.7% in the CPCPH subgroup with PVR greater than 3 WU (wide CI spanning zero). At day 29, echocardiography suggested persistence of effect, with LVEF up 19.4% (+9.0% to +29.8%), RVFAC up 20.3% (+3.2% to +37.3%), and TAPSE/SPAP up 36.3% (+11.3% to +61.2%). TX45 was well tolerated with no severe adverse events and no clinically significant blood pressure changes, aside from transient, asymptomatic decreases within 24 hours.
The core development is Tectonic Therapeutics’ Phase 1b Part B open-label, acute hemodynamic readout in Group 2 pulmonary hypertension associated with heart failure with reduced ejection fraction. The study extends an earlier PH-HFpEF signal to HFrEF and supports evaluating TX45, a long-acting Fc-relaxin fusion protein, across both phenotypes of Group 2 PH. In parallel, the company is running the 24-week APEX Phase 2 trial in PH-HFpEF enriched for CpcPH with PVR greater than 3 WU, with topline results expected in 2026.
Strategically, broadening into HFrEF is an expansion play that tests whether RXFP1 agonism can address the combined post- and pre-capillary pathophysiology that has frustrated traditional vasodilators in left heart disease. The choice to foreground catheter-based hemodynamics and day-29 echocardiography is deliberate: PCWP, TPR, and mPAP are tightly linked to exercise capacity and outcomes in Group 2 PH, and the left-sided pressure reductions differentiate TX45 from agents that primarily dilate the pulmonary bed and risk precipitating pulmonary edema. The tension is obvious: an open-label, 14-patient dataset with wide confidence intervals on PVR is not a regulatory argument, and translation from acute hemodynamics to sustained functional benefit remains unproven in this population.
For research sites, the program pushes toward more rigorous phenotyping and invasive assessments. CPCPH enrichment and PVR thresholds will increase screening friction and concentrate enrollment in centers with right heart catheterization, echo core-lab participation, and HF-PH co-management. The single-dose, long-acting profile may simplify visit flow, but the data burden will sit with experienced cath labs and imaging infrastructure. Sponsors and CROs will need to calibrate endpoints beyond catheter metrics—six-minute walk distance, KCCQ, NT-proBNP, and event-driven composites—while managing hypotension vigilance on background GDMT. Regulators have been cautious in Group 2 PH; durable improvements in exercise capacity and clinical status, not just surrogates, will be decisive. For patients, the absence of approved therapies in PH-LHD keeps the bar high but the opportunity meaningful.
Next, watch whether APEX confirms sustained benefit in an enriched HFpEF population and whether Tectonic initiates a dedicated HFrEF Phase 2 with similar CpcPH targeting. Dose regimen, durability beyond 29 days, and immunogenicity under repeat dosing will shape development risk. Operationally, enrollment pace in narrowly defined CPCPH, the balance of cardiology versus pulmonary site leadership, and core-lab throughput will determine timelines. The pivotal question is whether acute reductions in left-sided filling pressures and pulmonary afterload translate into functional gains and fewer decompensations over months. If that bridge is crossed, the company’s path broadens from HFpEF-first to a dual-phenotype program; if not, the signal risks remaining a catheterization artifact in a population where regulators expect hard clinical benefit.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
